Investment Management Corp of Ontario Raises Position in Moderna, Inc. (NASDAQ:MRNA)

Investment Management Corp of Ontario raised its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 125.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 24,546 shares of the company's stock after purchasing an additional 13,678 shares during the period. Investment Management Corp of Ontario's holdings in Moderna were worth $1,021,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Wilmington Savings Fund Society FSB lifted its holdings in shares of Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after purchasing an additional 587 shares in the last quarter. Compass Planning Associates Inc bought a new position in Moderna during the fourth quarter valued at about $37,000. Venturi Wealth Management LLC increased its holdings in Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after buying an additional 664 shares during the last quarter. Crowley Wealth Management Inc. bought a new stake in Moderna in the fourth quarter worth about $41,000. Finally, Itau Unibanco Holding S.A. raised its position in Moderna by 51.2% in the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock worth $42,000 after acquiring an additional 343 shares during the period. 75.33% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have commented on MRNA. Citigroup started coverage on shares of Moderna in a report on Thursday, March 13th. They set a "neutral" rating and a $40.00 price objective on the stock. Leerink Partners decreased their price target on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a report on Thursday, January 16th. Morgan Stanley decreased their target price on Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 9th. Barclays cut their price objective on Moderna from $45.00 to $40.00 and set an "equal weight" rating for the company in a report on Friday, May 2nd. Finally, Bank of America lowered their target price on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research note on Tuesday, February 11th. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $53.95.

Moderna Price Performance

MRNA traded up $1.21 during trading on Friday, hitting $24.86. 14,835,486 shares of the stock traded hands, compared to its average volume of 7,741,650. The firm has a market capitalization of $9.61 billion, a P/E ratio of -2.68 and a beta of 1.99. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $170.47. The firm has a 50-day moving average of $28.05 and a 200 day moving average of $35.78.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.92) by $0.40. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The company had revenue of $108.00 million for the quarter, compared to analysts' expectations of $130.35 million. During the same period last year, the firm earned ($3.07) earnings per share. Moderna's quarterly revenue was down 35.3% on a year-over-year basis. As a group, equities analysts predict that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.